Date: 2016-04-12
Type of information: Construction of new premises
Compound:
Company: GE Healthcare (USA - WI)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On April 12, 2016, GE Healthcare’s Life Sciences business announced that its European manufacturing and distribution site for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids and cell culture media, and launched a rapid production service for prototype cell culture media and buffers. The site in Pasching, Austria, mirrors the high quality and performance standards of the business’ Center of Excellence in Logan, Utah. The Pasching facility serves biopharmaceutical companies in over 40 countries across Europe, Africa and the Middle East. GE’s Pasching site now also offers Rapid Response Production services, enabling production of small volumes of prototype cell culture media and buffers within five days of ordering. The use of consistent and replicable manufacturing practices supports efficient future transfer to cGMP production for biomanufacturers. GE’s additional production capacity at Pasching has been developed over two years, with an investment of $4.3m USD (€3.8m). The site is also a production and distribution centre for Europe, with more than 300,000 individual product items shipped through the site per year.
Financial terms:
Latest news:
